Skip to main content

Advertisement

Table 5 Results of the scenario 2 and one-way sensitivity analyses (24 weeks)

From: Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea

Variables Input values Incremental costs (US $) Incremental QALY ICER (US $ per QALY gained)
Base case   466 0.0370 12,598 (₩14,198,501/QALY)
Cost ratio from Berry 2001 [27]   483 0.0370 13,065
  NYHA class I 0.049    
  NYHA class II 0.049    
  NYHA class III 0.120    
  NYHA class IV 0.831    
FCM price ± 15% (US $) 136-184 370-562 0.0370 10,009-15,188
Total number of FCM vials ± 1 vial 3-5 306-626 0.0370 8,282-16,915
CHF medical cost ± 25% (US $) 1,185-1,975 421-512 0.0370 11370-13,827
Effect-onset time 6th day 466 0.0370 12,598
Baseline CHF patient distribution from the expert survey   191 0.0370 5,165
  NYHA class II 58.3%    
  NYHA class III 41.7%    
  1. (US $1 = Kor ₩1,127).
  2. CHF, chronic heart failure; FMC, ferric carboxymaltose; ICER, incremental cost-effectiveness ratio; NYHA, New York Heart Association.
  3. Utility gains in scenario 2 were not changed according to variation of inputs because the utilities were directly obtained from the quality-of-life results at the follow-up periods in the FAIR-HF study.
  4. As the CHF medical cost increased, the ICER decreased.